- Home
- EWTX
as 05-08-2025 4:00pm EST
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 1.2B | IPO Year: | 2021 |
| Target Price: | $40.13 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.60 - $38.12 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Edgewise Therapeutics Inc. (EWTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Carruthers R Michael | EWTX | Chief Financial Officer | May 1 '25 | Sell | $16.45 | 1,314 | $21,620.82 | 81,014 | |
| Donovan Joanne M. | EWTX | CMO | May 1 '25 | Sell | $16.45 | 5,187 | $85,347.94 | 21,588 | |
| Russell Alan J | EWTX | Chief Scientific Officer | May 1 '25 | Sell | $16.45 | 1,551 | $25,520.46 | 18,521 | |
| Thompson Peter A. | EWTX | Director10% Owner | Apr 3 '25 | Buy | $20.13 | 496,771 | $10,000,000.23 | 14,809,075 | |
| ORBIMED ADVISORS LLC | EWTX | Director10% Owner | Apr 3 '25 | Buy | $20.13 | 496,771 | $10,000,000.23 | 14,809,075 | |
| KOCH KEVIN | EWTX | President and CEO | Mar 7 '25 | Sell | $30.00 | 100 | $3,000.00 | 14,478 | |
| Russell Alan J | EWTX | Chief Scientific Officer | Mar 7 '25 | Sell | $30.02 | 200 | $6,004.00 | 18,521 |
Latest Edgewise Therapeutics Inc. News
EWTX Breaking Stock News: Dive into EWTX Ticker-Specific Updates for Smart Investing
PR Newswire
13 hours ago
Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Insider Monkey
4 days ago
Is Edgewise Therapeutics, Inc. (EWTX) the Best Small Cap Stock to Buy with the Biggest Upside Potential?
Motley Fool
6 days ago
Why Edgewise Therapeutics Stock Popped This Week
MT Newswires
9 days ago
Guggenheim Starts Edgewise Therapeutics With Buy Rating, $41 Price Target
Insider Monkey
13 days ago
Is Edgewise Therapeutics Inc. (NASDAQ:EWTX) the Most Promising Small-Cap Stock According to Analysts?
BioPharma Dive
24 days ago
Bristol Myers stumbles in bid to widen heart drug’s use
Zacks
a month ago
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb
Zacks
a month ago
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More
Compare EWTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EWTX Edgewise Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.